Alvotech (NASDAQ:ALVO – Get Free Report) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.
Insider and Institutional Ownership
4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 0.5% of Alvotech shares are held by insiders. Comparatively, 0.9% of Valion Bio, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Volatility & Risk
Alvotech has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Alvotech and Valion Bio, Inc. Common Stock, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alvotech | 2 | 1 | 4 | 0 | 2.29 |
| Valion Bio, Inc. Common Stock | 1 | 0 | 0 | 0 | 1.00 |
Alvotech currently has a consensus target price of $8.50, indicating a potential upside of 73.82%. Given Alvotech’s stronger consensus rating and higher possible upside, analysts clearly believe Alvotech is more favorable than Valion Bio, Inc. Common Stock.
Profitability
This table compares Alvotech and Valion Bio, Inc. Common Stock’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alvotech | -36.31% | N/A | -11.73% |
| Valion Bio, Inc. Common Stock | N/A | -193.17% | -67.10% |
Valuation & Earnings
This table compares Alvotech and Valion Bio, Inc. Common Stock”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alvotech | $588.90 million | 2.51 | $27.92 million | ($0.61) | -8.02 |
| Valion Bio, Inc. Common Stock | $780,000.00 | 0.70 | -$8.88 million | ($159.25) | -0.00 |
Alvotech has higher revenue and earnings than Valion Bio, Inc. Common Stock. Alvotech is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.
Summary
Alvotech beats Valion Bio, Inc. Common Stock on 9 of the 13 factors compared between the two stocks.
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
About Valion Bio, Inc. Common Stock
Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
Receive News & Ratings for Alvotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alvotech and related companies with MarketBeat.com's FREE daily email newsletter.
